文章核心观点 - 实验室服务提供商Labcorp即将于2024年10月24日公布第三季度业绩 [1] - Labcorp在过去四个季度中均超出了预期,平均超出幅度为2.80% [1] - 第三季度Labcorp的收入预计将同比增长6.7%至32.6亿美元,每股收益预计将同比增长3.3%至3.49美元 [2] 诊断实验室(Dx)业务 - Dx业务占Labcorp总收入的近78%,预计将表现强劲 [4] - Labcorp与Naples Comprehensive Healthcare的合作有助于提高佛罗里达西南地区患者的检测服务可及性 [4] - 收购Invitae有望提升Labcorp的专业检测能力,为肿瘤和某些罕见疾病提供基因检测解决方案 [4] - 收购BioReference Health的部分资产有助于扩大Labcorp的实验室服务网络和临床服务 [5] - Labcorp推出多项新的检测解决方案,如结直肠癌微量残留疾病检测、血友病B基因治疗伴随诊断等,有望带动收入增长 [5][6] - Labcorp与Ultima Genomics的合作有助于提高可负担的遗传检测服务的可及性 [6] - Labcorp OnDemand平台上的健康和福祉检测服务种类不断增加,也有望带动收入增长 [6] 生物医药实验室服务(BLS)业务 - BLS业务的中央实验室业务表现强劲,新的Global Trial Connect套件有望被客户广泛采用 [7] - 早期开发业务的毛订单和取消率有所改善,有利于BLS业务收入 [7] - BLS业务收入预计将同比增长2.2% [7] 其他 - Labcorp的Launchpad计划有望为公司带来1亿至1.25亿美元的成本节约,有利于利润率改善 [8] - 根据公司的盈利预测模型,Labcorp本季度业绩可能难以超出预期 [9]

BURLINGTON, N.C., Oct. 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 13, 2024, to stockholders of record as of the close of business on November 26, 2024. About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, phar ...

文章核心观点 - 公司在细胞和基因疗法、向消费者市场拓展以及通过专业检测和生物制药业务实现国际增长方面表现出色 [1][2] - 公司的生物制药业务从与制药和生物技术公司的合作中获益,中央实验室业务增长强劲,早期开发业务也在逐步恢复 [3] - 公司通过"LaunchPad"计划持续提升利润率,成本节约目标为每年1亿-1.25亿美元 [4] - 但公司面临宏观经济不确定性和汇率波动带来的挑战,成本和费用上升 [5][6] 行业和公司概况 - 公司是一家专注于诊断检测和药物开发服务的公司,业务受全球经济状况和地缘政治局势的影响 [5] - 公司在国际市场的大量业务使其面临汇率波动的风险,近期美元升值对公司海外收入造成一定负面影响 [6] - 公司采取了一系列战略举措,如拓展高增长领域、实施成本节约计划等,以应对挑战,推动业务发展 [1][2][4]

Labcorp Holdings Inc. (LH) is making strides in expanding testing solutions in strategic growth areas. The company is improving its margin performance through the benefits of the LaunchPad initiative, which is nearing its targeted savings goal. Its strategic partnerships with health systems and regional labs are also poised to boost growth in the upcoming quarters. Meanwhile, uncertain macroeconomic conditions and a debt-laden balance sheet raise worry for Labcorp's operations. In the past year, this Zacks ...

BURLINGTON, N.C., Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2024 before the market opens on Thursday, October 24, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webca ...

Labcorp (LH) has announced the expansion of its molecular bioanalytical laboratory in Greenfield, IN. The expanded facility will increase the company's global molecular bioanalytical capacity, enabling the company to help biopharmaceutical customers bring life-saving advanced therapies to patients faster. The latest development is expected to positively boost the company's Central Laboratories business under the Biopharma Laboratory Services ("BLS") segment. Predicting LH Stock Movement Following the News S ...

The American College of Obstetricians and Gynecologists (ACOG) recommends postpartum care be treated as an ongoing process rather than a single doctor's visit. However, estimates suggest that a significant number of women do not attend even one postpartum appointment, in part due to access barriers like lack of health insurance, transportation and childcare. "The postpartum period is a precarious time for women in the United States. Current standards of care provide insufficient support for women who may be ...

Labcorp Holdings Inc. (LH) recently announced the completion of its acquisition of select assets of BioReference Health — a wholly-owned subsidiary of OPKO Health, Inc. (OPK). The transaction is aimed at providing customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions across the United States. Likely Trend of LH Stock Following the News Following the announcement, shares of Labcorp rose 2.1% to $225.76 ...

BURLINGTON, N.C., Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of $2,000,000,000 in senior notes (the Offering). The Offering consists of three tranches: $650,000,000 aggregate principal amount of 4.350% Senior Notes due 2030 (the 2030 Notes), $500,000,000 aggregate principal amount of 4.550% Senior Notes due 2032 (the 2032 Notes) and $850,000,000 aggregate ...

Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI, Sept. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. The transaction is expected to provide ...